A theory explaining why psychosis-linked drugs can also relieve psychiatric symptoms | Research

The takeaway

A new theoretical framework proposes that drugs like cannabis and psychedelics can both relieve psychiatric symptoms (compensation) and increase psychosis risk (sensitization) through the same neurotransmitter systems.

People interested in why cannabis can be both therapeutically beneficial and psychosis-linked.

Compensation vs. sensitization: short-term relief vs. long-term risk

What the researchers found

The authors introduce "psychotomimetic compensation" (short-term symptom relief via endocannabinoid, serotonergic, glutamatergic, and dopaminergic systems) and "psychotomimetic sensitization" (gradual intensification of psychotic-like experiences after repeated drug/stress exposure) to explain how the same drugs can both help and harm.

Why it matters

It has long been a paradox that cannabis can relieve symptoms like pain and depression while also being linked to psychosis risk. This framework offers a coherent explanation: short-term engagement of certain neurotransmitter systems provides compensation, while repeated exposure leads to sensitization.

The numbers in context

Four neurotransmitter/modulator systems identified: endocannabinoid, serotonergic, glutamatergic, and dopaminergic. Applies to multiple drug classes: cannabinoids (pain), amphetamines (attention/motivation), psychedelics/dissociatives (depression).

How the study worked

Theoretical paper synthesizing existing evidence on psychotomimetic drugs (cannabis, amphetamines, psychedelics, dissociatives) to propose a unified explanatory model for their paradoxical therapeutic and psychosis-inducing effects.

What this study cannot tell us

This is a theoretical model, not an empirical study. The framework synthesizes existing data but does not generate new evidence. Individual variability in compensation vs. sensitization thresholds is not addressed.

How to read the evidence

This is a theoretical paper proposing a new conceptual framework. It synthesizes existing evidence but does not present new empirical data, so evidence grading does not apply.

When this study was published

Published in 2024 in Pharmacology Research & Perspectives.

The bigger picture

As cannabis and psychedelics gain traction as therapeutic agents, understanding why the same compounds can both treat and cause psychiatric problems is essential. This compensation vs. sensitization model could guide safer therapeutic protocols by distinguishing short-term benefit from long-term risk.

Questions still open

What determines whether an individual experiences compensation or sensitization? Can therapeutic protocols be designed to maximize compensation while minimizing sensitization risk? Is there a threshold of use frequency below which sensitization does not occur?

Common questions

How can the same drug both help and cause psychosis?

The authors propose that short-term drug exposure engages neurotransmitter systems in a compensatory way that relieves symptoms, while repeated exposure gradually sensitizes those same systems, increasing the risk of psychotic-like experiences over time.

Does this apply specifically to cannabis?

Cannabis is one of several drug classes the model covers. The same paradox applies to amphetamines (help attention but linked to psychosis), psychedelics (help depression but are psychotomimetic), and dissociatives.

Read the original research

Psychotomimetic compensation versus sensitization.

Pharmacology research & perspectives, 12(4), e1217

View on PubMed ↗Publisher’s paper ↗

Citation

Brouwer, Ari; Carhart-Harris, Robin L; Raison, Charles L. (2024). Psychotomimetic compensation versus sensitization.. Pharmacology research & perspectives, 12(4), e1217. https://doi.org/10.1002/prp2.1217